Caleb Lee

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi, Cristina Saura, Toshinari Yamashita et al. · New England Journal of Medicine · 2019 · 1.9K citations · Full text

Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

Shanu Modi, Haeseong Park, Rashmi K. Murthy et al. · Journal of Clinical Oncology · 2020 · 786 citations · Full text

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Toshihiko Doi, Kohei Shitara, Yoichi Naito et al. · The Lancet Oncology · 2017 · 474 citations

Breast Oncology, Oncology, Medicine +10

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study

Kenji Tamura, Junji Tsurutani, Shunji Takahashi et al. · The Lancet Oncology · 2019 · 343 citations

Breast Oncology, Oncology, Breast Cancer +6

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Guy Jérusalem, Yeon Hee Park, Toshinari Yamashita et al. · Cancer Discovery · 2022 · 97 citations · Full text